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The diversity of MS in Asia has been a topic of
debate for years. Although the prevalence of MS
varies in different parts of this region (with Israel, the
Middle East and west-Asian countries having the
highest reported MS prevalences), nationwide MS
surveys have rarely been undertaken, and differences
in the availability of advanced medical care for MS
patients may confound cross-border comparisons. 
We believe that there are wide variations in the
clinical presentation, male to female ratio and human
leucocyte antigen (HLA) typing among MS patients
throughout Asia. In addition, it is a matter of debate
whether clinical and immunological features of Asian
MS patients as a group are distinct from European or
North American MS patients. For example, although
opticospinal MS (OSMS) is reported to be common
in Japanese literature and is sometimes referred to as
Asian-type MS, this term may be misleading.
Neuromyelitis optica – which is similar to OSMS in
many respects – is found globally. It may be that
historical variations in diagnostic criteria may be a
major factor in the perceived excess of opticospinal-
type MS cases in Asia. Moreover, in some Asian
countries, OSMS is reported to be rare. 
An extensive and systematic review of how MS is
reported in Asia has not previously been undertaken.
In the present study, therefore, we reviewed
published MS-related literature (in the English
language) from 22 Asian countries. 
Methods
A MEDLINE® search using the key words ‘multiple
sclerosis’ and names of countries was performed,
covering the period from 1970 to 2005. In total,
432 articles were identified, and papers published in
English were included. Only epidemiological studies
or case series larger than 15 patients were included.
As a result, we reviewed 105 articles. Asian
countries were divided into four geographical
regions – eastern, southern, western, and central – to
identify regional or racial differences in MS across
the continent. We compared data from countries
within each region in tabulated form. Data were
input onto a pre-specified questionnaire that focused
on prevalence, male to female ratio, clinical
presentation (particularly opticospinal cord
involvement) and HLA typing.
Results
Eastern Asia
There is relatively limited literature in the English
language on MS from this region. We reviewed
papers from Japan,1–7 China,8,9 Hong Kong,10–12
Taiwan,13 Singapore,14 Thailand,15,16 Korea17 and
Malaysia.18 No papers were available from Vietnam,
Cambodia or Indonesia.
In this region, the MS prevalence is estimated to
be between 0.8 and 2 cases per 100 000 (Table 1),
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Summary
This paper reviews all available English language
literature on MS from Asian countries published between
1970 and 2005. Although limited data are available, the
review reveals that western Asia – including the Middle
East – has the highest prevalence of MS across the
continent, and that MS in Asia largely resembles
conventional MS in western countries. Opticospinal MS 
(a distinct clinical entity from conventional MS) is more
common in eastern Asian regions. Larger epidemiological
and genetic studies, with more complete ascertainment in
various Asian populations, are needed so that we can
understand the diversity of Asian MS. 
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although not all countries have prevalence data. A
recent paper from northern Japan,6 however,
reported a higher prevalence of 8.57 cases per
100 000 population. An increase in the incidence,
change in the diagnostic criteria, and the role of
magnetic resonance imaging (MRI) in the diagnosis
of MS may explain this apparent rise. 
Female preponderance is reported by all series
except Kurtzke et al.17 The male to female ratio ranges
from 1:1.3 to approximately 1.5. An unusually lower
male to female ratio of 1:9.6 was reported from Hong
Kong10 in a 2002 article. The mean age of MS onset
across Asia ranges from 25 to 33 years.
Chiemchanya and Vishudhiphan16 found MS in 17
paediatric patients from Thailand, six of whom
developed the disease before 5 years of age. For most
patients, disease onset was acute (<1 week) or
subacute (1 week to 1 month), and optical symptoms
and/or spinal cord involvement at onset and during
the disease course were common (Table 1). 
The prominence of opticospinal involvement in
Asian populations has long been recognized. Many
authors have divided MS into opticospinal and
conventional forms, based on their differential clinical
phenotypes. Kira et al. 5 consider these to be
different clinical entities and have also shown
immunogenetic differences between the types: they
found an association between conventional MS and
the DRB1*1501 and DRB5*0101 alleles in MS
patients, but not those with opticospinal involvement.
A subsequent paper4 demonstrated a change in the
clinical phenotype of MS in Japan over a 50-year
period, identifying an increasing incidence of
conventional MS and a concomitant decrease in the
incidence of OSMS. Others have reported similar
trends.19
High mortality rates (6–36%) have been
described, with the mean duration of illness being
between 20 months and 8 years before death in
some countries.9,11,13,15,16,18 The pathological
findings from autopsies (which represent very few
cases) show extensive opticospinal involvement. In
addition to classic demyelinating lesions, destructive,
necrotic lesions with hypercellularity have been
found.11,13
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Southern Asia
Southern Asia (India, Pakistan, Bangladesh, Sri Lanka,
Nepal, the Maldives and Bhutan), Iran, Myanmar and
Afghanistan are considered to be areas of low MS
prevalence (<5 per 100 000 population).20–23 There
are no published reports in English from Bangladesh,
Nepal, the Maldives, Bhutan, Afghanistan and
Myanmar. Literature on the subject is scarce from
Pakistan,24 Sri Lanka25 and Iran,20,26 although several
reports are available from India, 21,27–34 the majority
being hospital-based case series. 
There are no nationwide prevalence reports from
these countries, although two community-based
prevalence studies from India, conducted in the late
1980s, revealed a prevalence of 21–58 per 100 000
population among the Parsi community.31,32 MS
diagnosis in both of these surveys was based on
Schumacher’s criteria. In a hospital-based study,
Gangopadhyay et al.21 reported an incidence of 0.62
per 100 000 population based on patients who visit
neurology outpatient clinics. Although a population-
based survey in Indian Kashmir, conducted in 1986,
failed to detect any MS cases, another hospital-based
study showed that, over time, the total proportion of
MS-related neurology department admissions
increased from 1.58% to 2.54%.28 This apparent rise
is likely to be multifactorial and has been linked to
increased awareness (possibly because of a growing
number of neurologists) and the availability of
sophisticated diagnostic tools, especially MRI. 
In general, research undertaken since the 1990s
indicates that MS affects more women than men,35
although, an earlier Indian paper indicated a male
preponderance. 27 The mean age of MS onset has
been reported between 25 and 30 years (Table 2)
(ranging from 4.5 years27 to 55 years21). Kalanie 
et al.20 found a higher age of onset for patients with
progressive disease, especially primary-progressive
MS, which is also recognized in Western countries.36
Visual symptoms were the most common
presenting features (followed by motor symptoms) in
Indian patients,27 while in Iran, motor manifestations
were the most common, followed by sensory and
visual symptoms in that order.20 Cerebellar
involvement was both less common at onset and was
relatively less frequent during the course of illness
compared with expectations with western-type MS.
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Key Points
• The prevalence of MS is high in western Asia
and the Middle East compared with eastern or
south-eastern Asia
• Opticospinal MS is more common in eastern
Asia; patients from western or south-eastern Asia
predominantly suffer from western-type MS
• The genetic make-up of patients with MS in
western Asia is probably closer to Caucasians
than those from eastern Asia
• Large multicentre studies, involving all Asian
countries, are needed to understand the
epidemiology and course across the continent
The reported frequency of OSMS is 23–33% in the
majority of Indian papers,21,27, 29 but some studies
report as high as 47–58%27,28, whereas OSMS is
relatively less common in Iran.20 Common presenting
features in Sri Lankan patients were visual and
pyramidal, which is consistent with reports of
western-type MS.25 No papers describing the clinical
manifestations of MS in Pakistan have been published.
Few studies from India have identified an
immunological or genetic basis for MS, although one
case-control study found that measles infection and
exposure to dogs were significantly more common in
MS patients than in controls.37 An Iranian study
found that 5% of patients had a family history of MS
in first-degree relatives,20 but an Indian study failed
to detect a single case with a positive MS history in
a first-degree relative.30 Various HLA antigens have
been noted to be more common in MS patients
compared with the general population, although the
frequency of HLA markers from people born in this
region differs from that reported in western literature.
An Iranian study26 found a higher occurrence of HLA
DR2, DR15 and A24 in patients with definite MS,
with a relative risk of 1.9 for each marker. Indian
investigators33,34 identified an association between
HLA B12 and MS: this antigen was detected in about
80% of cases, compared with about 15% of controls. 
There is little information on disability and
prognosis in people with MS from this region,
although the clinical course of MS tends to be more
severe compared with patients from western
countries, with higher percentages of southern Asian
patients being severely disabled or bedridden. Some
papers have included Expanded Disability Status
Scale (EDSS) scores of <5 in most patients,20,21 and
annual attack rates of 0.4 from Iran20 and 0.63 from
India,28 in patients with relapsing–remitting MS. The
median EDSS score for Indian patients was 3.7
(mean of 6 years from disease onset),21 whereas it
was 2.1 in Iran at 5.5 years post onset.20 The
Iranian investigators20 also noted that 12% of their
patients had EDSS scores <2 at 5 years and 14%
had EDSS scores <3 at 10 years.
Western Asia and Middle East
This region can be considered as a medium-risk zone
for MS, where the disease prevalence is 5–29 per
100 000 population, as opposed to a high-risk zone
(prevalence rates >30 per 100 000 population), or
low-risk zone (prevalence <5 per 100 000
population).38 Surveys from the Middle East have
demonstrated MS to be less common in this region
compared with western Europe and North America,
but the prevalence of MS in this region is higher than
in any other part of Asia. A limited number of English
language papers on MS from this region have been
published. We reviewed papers from Kuwait,39,40
Turkey,41 Jordan,42 Iraq,43,44 Israel,45–47 and Saudi
Arabia.48–50 No English language papers were
available from Qatar, United Arab Emirates, Syria,
Palestine, Yemen, Bahrain, Oman and Lebanon.
Excluding Israel and Turkey, most west-Asian
countries have predominantly Arab populations. The
MS prevalence is approximately 10–20 per 100 000
population (Table 3), compared with 30–80 per
100 000 population in North America. One study,
however, reported a higher extrapolated prevalence
of 20 per 100 000 Jordanians and 42 per 100 000
Palestinians.42 The prevalence of MS in Palestinians
is reported to be the highest among Arab
countries.39,40,42 Palestinians living in Kuwait also
have a higher incidence of MS than native Kuwaitis;
reasons for this are unclear, but may be related to
the admixture of northern European peoples who
have settled in this area during migration or
invasion. A similar explanation may apply for other
non-Arab nations – including the Kurds who live in
northern Iraq – who also have higher MS prevalence
rates than others native to these regions.43,44
The MS prevalence was found to be 0.4/100 000
in Saudi Arabia.48 Israel, however, is considered to
be a high-risk zone for MS with a prevalence of more
than 30 per 100 000 population,45 with higher rates
in native Jews of Asian/African origin (52/100 000)
than immigrant Jews of Asian/African origin
(22/100 000).47 In Turkish people, the male to
female ratio of MS ranged from 1:1.1 to 1:1.9.41 
The mean age of MS disease onset in this Asian
region ranges from 12 to 34 years, although local
studies have rarely assessed the signs, symptoms and
course of MS. The few that have done so have
usually studied Arab populations, in whom the most
common symptoms are visual loss and sensory
symptoms. Daif et al.49 reviewed 89 MS cases and
Yaqub and Daif50 reported 16 cases; both studies
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Table 2: Characteristics of MS in India and Iran
Lead author/
Reference No. Jain27 Syal28 Mani29 Gangopadhyay21 Bansil30 Kalanie20
Years covered by study 1957–1980 1986–1998 1991–1996 1989–1999 1990s 1996–2001
Population Indian Indian Indian Indian Indian Iranian
No. of patients 354 100 31 45 81 200
Mean age of 27 28.5 25.3 30.5 27.5 27.0
onset (years)
Males:females 
with MS 1:1.32 1:1.32 1:2.10 1:1.50 1:2.25 1:2.50
Optic-spinal 
presentation (%) 22–58 47 23 33 – 20
–, not reported
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Table 3: Characteristics of MS in the Middle East
Lead author/
Reference no. Al-Din39 Al-Din40 Kantarci41 Karni47 Al-Din42
Year of publication 1990 1986 1998 2003 1995
Kuwaitis and Kuwaitis Turkish Israel Jordanians
Population Palestinians
No. of patients 201 89 1259 272 139
Prevalence per 
100 000 10.2 8.33 – 46.2 20.0
Males:females 
with MS 1:1.7 1.11:1 1:1.19 1.64:1 1:1.9
Mean age of 
onset (years) 34.7 31.2 27.6±8.8 – 29.6±8.1
Opticospinal 
presentation (%) – 27 25 – 28
–, not reported
were undertaken in Saudi Arabia and found the
presentation and course of MS in these patients to be
no different to western MS. A review of 300 Iraqi
patients included clinical and demographic data
similar to Caucasian populations.43 
A significant association between MS and HLA-
DR2 and HLA-DQW1 was found in Palestinians,39
and a population-based cohort of clinically definite
MS patients showed a significant association
between HLA class II alleles (DRB1, DQA1, DQB1)
and MS, in Ashkenazi and non-Ashkenazi Jewish
populations.45 These data also suggested that
DRB1*1501 is the susceptibility allele for MS in the
Jewish population.45 An Israeli MS study showed that
Ashkenazi Jews originating from Northern Europe
had the highest ∆32CCR5 allele frequency, and that
the ∆32CCR5 mutation, correlated with slower MS
disease progression.51
Central Asia
Literature from this region published in the English
language is limited. We reviewed four papers from
Uzbekistan and Tajikistan.52–55 The Tajikistani study
reviewed 182 patients with conventional MS and
suggested climatic factors for pathogenesis.52 Three
studies by Alaev et al.53–55 reviewed over 100 MS
cases from Uzbekistan, concluding that MS was more
common in people of Russian descent compared with
those of Uzbeki origin. OSMS was not specifically
mentioned in these studies. 
Discussion
The present study presents a systematic and
comprehensive review of the prevalence and clinical
presentation of MS throughout Asia. Our findings are
greatly limited by the weakness of available data
and the extreme variability of ascertainment bias,
which could influence prevalence, gender ratio,
disease subtypes, clinical course and genetic
associations. The data are also limited by the
variable quality of the different studies, small sample
sizes, diagnostic difficulties, and incomplete and
variable reporting methods. Most studies were
hospital-based case series rather than population-
based studies, which limited the scope of our review.
Although reports or case series from many Asian
countries have not been published, we believe that
MS exists throughout the Asian region. The MS
diagnosis is closely related to the availability of
neurologists and diagnostic tools, therefore the
prevalence of MS in developing countries may
increase when access to these services is more
widespread. 
The overall prevalence of MS in Asia is lower than
in Europe or North America, which may in part be
related to genetic factors. In support of this conclusion,
the prevalence of MS in Asians born in western
countries is lower than that of the native
population.56,57 Large epidemiological studies are
needed to study MS incidence and prevalence, and its
natural disease course, in developing Asian countries. 
Although OSMS is perceived to be more common
in Asia than elsewhere, such findings mostly emerge
from research undertaken in eastern Asia rather than
across the continent.58 Reports from India, Iran, the
Middle East and Iraq show OSMS to be rarer in these
countries than in eastern Asia. OSMS is uncommon –
although it may be more correct to say under-
recognized – in North America, because the disease
has traditionally been diagnosed only in those with
classic features of Devic’s disease. This form of MS is
more common in African–Americans  compared with
Caucasian Americans.59 Various reports suggest that
OSMS is clinically, radiologically and immunologically
distinct from conventional MS,60–70 although another
study suggests that OSMS and neuromyelitis optica
may be the same condition.71 Our literature review is
unable to differentiate the true prevalence of
neuromyelitis optica or OSMS from cases of western
MS with optic and spinal involvement, primarily
because the criteria that allow these entities to be
differentiated have only recently emerged.
It is generally felt that neuromyelitis optica or
OSMS do not respond to interferon therapy. Recent
research, however, indicates a trend in favour of high-
dose beta interferon therapy for reducing relapses in
people with opticospinal MS, although the results
were not statistically significant.72 Further studies are
needed to establish whether patients with opticospinal
MS do respond to beta interferon therapy.
Finally, one should note that it is extremely difficult
to compare genetic characteristics of western and
Asian MS: the Asian subcontinent comprises racially
and geographically diverse populations, and few
studies from Asian countries have reported HLA
typing in MS patients. Available data, however,
suggest that the genetic make-up of MS patients from
western Asia is probably closer to that of Caucasians
than of those from eastern Asia.73 
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